# Cilostazol and Aspirin for Cardiovascular Event Prevention in Patients With Type 2 Diabetes

> **NCT07719894** · PHASE4 · RECRUITING · sponsor: **Seoul National University Bundang Hospital** · enrollment: 1200 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus (T2DM)
- Atherosclerosis

## Interventions

- **DRUG:** Cilostazol
- **DRUG:** Aspirin

## Key facts

- **NCT ID:** NCT07719894
- **Lead sponsor:** Seoul National University Bundang Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-06
- **Primary completion:** 2028-12
- **Final completion:** 2028-12-31
- **Target enrollment:** 1200 (ESTIMATED)
- **Last updated:** 2026-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07719894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07719894, "Cilostazol and Aspirin for Cardiovascular Event Prevention in Patients With Type 2 Diabetes". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07719894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*